Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report

doi:10.12998/wjcc.v12.i11.1967

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1884)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

942

Figures (1-2)

239

Tables (1-1)

226

Sum=1452

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

284

Sum=365

Apr 16, 2024 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Apr 16, 2024; 12(11): 1967-1973
Published online Apr 16, 2024. doi: 10.12998/wjcc.v12.i11.1967

Table 1 Treatment process

Date (year, month)	Treatment methods	Duration
June 2014	Operation	/
July 2014-January 2015	TC chemotherapy	6 months
January 2018-June 2018	CD chemotherapy	6 months
August 2018-August 2019	Targeting drug (olaparib)	1 year
September 2019-November 2019	TC chemotherapy	3 months
December 2019-February 2020	CD chemotherapy	3 months
April 2020-December 2022	Anti-PD-1 therapy (tislelizumab)	32 months
December 2022-January 2024	Without any treatment.	13 months

TC: Paclitaxel and carboplatin; CD: Carboplatin and doxorubicin hydrochloride liposome; PD-1: Programmed cell death-1.

Citation: Zhou GD, Li Q. Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report. World J Clin Cases 2024; 12(11): 1967-1973
URL: https://www.wjgnet.com/2307-8960/full/v12/i11/1967.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i11.1967